• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Creation of a generalized model prediction of inhibition of neuraminidase of influenza virus of various strains

tetano

Editor, Senior Moderator
Biomed Khim. 2018 Jun;64(3):247-252. doi: 10.18097/PBMC20186403247.
[h=1][Creation of a generalized model prediction of inhibition of neuraminidase of influenza virus of various strains].[/h] [Article in Russian; Abstract available in Russian from the publisher]
Mikurova AV[SUP]1[/SUP], Skvortsov VS[SUP]1[/SUP].
[h=3]Author information[/h]

[h=3]Abstract[/h] in English, Russian
Preliminary results of construction of overall model for prediction of IC50 value of ligands of influenza virus neuraminidase of any strain are presented. We used MM-PBSA (MM-GBSA) energy terms calculated for the complexes obtained after modeling of 30 variants of neuraminidase structures, subsequent docking and simulation of molecular dynamics as independent variables in prediction equations. The structures of known neuraminidase-inhibiting drugs (oseltamivir, zanamivir and peramivir) and a neuraminidase substrate (MUNANA) were used as ligands. The correlation equation based on calculated energetic parameters of inhibitor complexes with neuraminidase did not result in the prediction of IC50 with acceptable parameters (R2?0.3). However, if information about binding energy of the substrate used for neuraminidase assay (and IC50 detection) is included the resulting IC50 prediction equations become significant (R2?0.55). It is concluded that models based on IC50 values as a predictable variable and combining information about binding of different ligands to different variants of the target proteins must take into account the binding properties of the substrate (used for IC50 determination). The predictive power of such models depends critically on the quality of the modeling of the ligand-protein complexes.


[h=4]KEYWORDS:[/h] QSAR; computational methods; influenza virus neuraminidase; inhibitors

PMID: 29964260
 
Back
Top Bottom